Literature DB >> 10497889

Effects of antiprogestins on the rate of proliferation of breast cancer cells.

K Iwasaki1, B Underwood, M Herman, S Dinda, S Kodali, H J Kloosterboer, C Hurd, V K Moudgil.   

Abstract

We have examined the influence of progestins (progesterone, R5020) and antiprogestins (RU486, ZK98299, Org 31710 and Org 31806) on the rate of proliferation of wild type T47D cells cultured in whole fetal bovine serum (FBS) or in single charcoal stripped fetal bovine serum (SSFBS). All of the progesterone antagonists RU486, ZK98299 and two novel antiprogestins Org 31710 and Org 31806 inhibited cell proliferation when cells were cultured in FBS. In contrast, all of the antiprogestins with the exception of ZK98299 enhanced cell growth when cells were cultured in SSFBS. This stimulatory effect of RU486 was observed only at a high concentration of the ligand (1 microM). The effect of R5020, however, was concentration independent. The number of cells in the presence of RU486 was approximately 600% followed by R5020 approximately 400% above control values after a 28 day culturing period. In contrast, when the cells were grown in the presence of medium containing non-stripped whole serum, RU486 inhibited the extent of cell proliferation by 45%. Estradiol (E2) stimulated the rate of proliferation in cells cultured in SSFBS. Similar to when cells were cultured in whole serum, the antiprogestins inhibited cell growth in E2-supplemented SSFBS. Detection of the growth enhancement effects of progesterone receptor (PR) ligands such as RU486 and R5020 on the cells grown in charcoal-stripped medium appear to require the removal of E2 by charcoal stripping of the serum.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10497889     DOI: 10.1023/a:1006945813508

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  26 in total

Review 1.  The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer?

Authors:  K B Horwitz
Journal:  Endocr Rev       Date:  1992-05       Impact factor: 19.871

2.  Receptors bound to antiprogestin from abortive complexes with hormone responsive elements.

Authors:  A Guiochon-Mantel; H Loosfelt; T Ragot; A Bailly; M Atger; M Misrahi; M Perricaudet; E Milgrom
Journal:  Nature       Date:  1988-12-15       Impact factor: 49.962

3.  Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells.

Authors:  R L Sutherland; R E Hall; G Y Pang; E A Musgrove; C L Clarke
Journal:  Cancer Res       Date:  1988-09-15       Impact factor: 12.701

4.  Hormone receptors: their role in predicting prognosis and response to endocrine therapy.

Authors:  W L McGuire
Journal:  Semin Oncol       Date:  1978-12       Impact factor: 4.929

5.  Regulation of tumor suppressor proteins, p53 and retinoblastoma, by estrogen and antiestrogens in breast cancer cells.

Authors:  C Hurd; N Khattree; S Dinda; P Alban; V K Moudgil
Journal:  Oncogene       Date:  1997-08-18       Impact factor: 9.867

6.  Steroid hormone receptors compete for factors that mediate their enhancer function.

Authors:  M E Meyer; H Gronemeyer; B Turcotte; M T Bocquel; D Tasset; P Chambon
Journal:  Cell       Date:  1989-05-05       Impact factor: 41.582

7.  Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cells.

Authors:  P G Gill; F Vignon; S Bardon; D Derocq; H Rochefort
Journal:  Breast Cancer Res Treat       Date:  1987-10       Impact factor: 4.872

8.  Characterization of R5020 and RU486 binding to progesterone receptor from calf uterus.

Authors:  C Hurd; V K Moudgil
Journal:  Biochemistry       Date:  1988-05-17       Impact factor: 3.162

9.  Novel antiprogestins Org 31806 and 31710: interaction with mammalian progesterone receptor and DNA binding of antisteroid receptor complexes.

Authors:  T Mizutani; A Bhakta; H J Kloosterboer; V K Moudgil
Journal:  J Steroid Biochem Mol Biol       Date:  1992-08       Impact factor: 4.292

10.  The antiprogestin RU38 486: receptor-mediated progestin versus antiprogestin actions screened in estrogen-insensitive T47Dco human breast cancer cells.

Authors:  K B Horwitz
Journal:  Endocrinology       Date:  1985-06       Impact factor: 4.736

View more
  8 in total

1.  Agonist and antagonist-induced qualitative and quantitative alterations of progesterone receptor from breast cancer cells.

Authors:  C Hurd; K Nag; N Khattree; P Alban; S Dinda; V K Moudgil
Journal:  Mol Cell Biochem       Date:  1999-09       Impact factor: 3.396

Review 2.  Deciphering the divergent roles of progestogens in breast cancer.

Authors:  Jason S Carroll; Theresa E Hickey; Gerard A Tarulli; Michael Williams; Wayne D Tilley
Journal:  Nat Rev Cancer       Date:  2016-11-25       Impact factor: 60.716

3.  SILEC: a protocol for generating and using isotopically labeled coenzyme A mass spectrometry standards.

Authors:  Sankha S Basu; Ian A Blair
Journal:  Nat Protoc       Date:  2011-12-08       Impact factor: 13.491

4.  Hormonal regulation of epithelial organization in a three-dimensional breast tissue culture model.

Authors:  Lucia Speroni; Gregory S Whitt; Joanna Xylas; Kyle P Quinn; Adeline Jondeau-Cabaton; Clifford Barnes; Irene Georgakoudi; Carlos Sonnenschein; Ana M Soto
Journal:  Tissue Eng Part C Methods       Date:  2013-06-25       Impact factor: 3.056

5.  Stable isotope labeling by essential nutrients in cell culture for preparation of labeled coenzyme A and its thioesters.

Authors:  Sankha S Basu; Clementina Mesaros; Stacy L Gelhaus; Ian A Blair
Journal:  Anal Chem       Date:  2011-01-26       Impact factor: 6.986

6.  CCM signaling complex (CSC) couples both classic and non-classic Progesterone receptor signaling.

Authors:  Johnathan Abou-Fadel; Xiaoting Jiang; Brian Grajeda; Akhil Padarti; Cameron C Ellis; Esmeralda Flores; Alyssa-Marie D Cailing-De La O; Jun Zhang
Journal:  Cell Commun Signal       Date:  2022-08-15       Impact factor: 7.525

7.  CmPn signaling networks in the tumorigenesis of breast cancer.

Authors:  Mellisa Renteria; Ofek Belkin; David Jang; Justin Aickareth; Muaz Bhalli; Jun Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-29       Impact factor: 6.055

8.  Elevated expression and altered processing of fibulin-1 protein in human breast cancer.

Authors:  L M Greene; W O Twal; M J Duffy; E W McDermott; A D Hill; N J O'Higgins; A H McCann; P A Dervan; W S Argraves; W M Gallagher
Journal:  Br J Cancer       Date:  2003-03-24       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.